文献速递白血病

选择性小分子UBA1抑制剂TAK-243在急性髓系白血病中的临床前评价

Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia.
PubMed 文献 · Leukemia · 2018-06-08

在急性髓系白血病(AML)细胞系和原代样本中,TAK-243诱导细胞死亡并抑制克隆生长,而正常造血祖细胞相对耐药;在体内,TAK-243降低白血病负荷并靶向白血病干细胞,且未观察到毒性证据;研究还鉴定了UBA1腺苷化结构域的错义突变与获得性耐药相关。

要点

  • TAK-243在AML细胞系和原代样本中诱导细胞死亡并抑制克隆生长。
  • TAK-243在体内降低白血病负荷并靶向白血病干细胞,无毒性证据。
  • TAK-243耐药AML细胞携带UBA1腺苷化结构域错义突变。

核心结论

  • TAK-243靶向AML细胞和干细胞,支持在该患者群体中开展临床试验。
  • 研究提供了对UBA1抑制剂获得性耐药潜在机制的见解。

研究设计与样本

  • 临床前研究,在AML细胞系和原代AML样本中评价TAK-243。
  • 在体内模型中评价TAK-243对白血病负荷和白血病干细胞的作用。
  • 筛选对TAK-243耐药的AML细胞群并鉴定UBA1突变。

主要发现

  • 在AML细胞系和原代AML样本中,TAK-243诱导细胞死亡并抑制克隆生长,而正常造血祖细胞相对耐药。
  • 在完整AML细胞中,TAK-243优先结合UBA1而非相关E1酶UBA2、UBA3和UBA6。
  • TAK-243抑制UBA1降低泛素化蛋白水平,并增加蛋白毒性应激和DNA损伤应激标志物。
  • 在体内,TAK-243降低白血病负荷并靶向白血病干细胞,无毒性证据。
  • 在TAK-243耐药AML细胞群中鉴定出UBA1腺苷化结构域的错义突变。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Acute myeloid leukemia (AML) is an aggressive hematologic malignancy for which new therapeutic approaches are required. One such potential therapeutic strategy is to target the ubiquitin-like modifier-activating enzyme 1 (UBA1), the initiating enzyme in the ubiquitylation cascade in which proteins are tagged with ubiquitin moieties to regulate their degradation or function. Here, we evaluated TAK-243, a first-in-class UBA1 inhibitor, in preclinical models of AML. In AML cell lines and primary AML samples, TAK-243 induced cell death and inhibited clonogenic growth. In contrast, normal hematopoietic progenitor cells were more resistant. TAK-243 preferentially bound to UBA1 over the related E1 enzymes UBA2, UBA3, and UBA6 in intact AML cells. Inhibition of UBA1 with TAK-243 decreased levels of ubiquitylated proteins, increased markers of proteotoxic stress and DNA damage stress. In vivo, TAK-243 reduced leukemic burden and targeted leukemic stem cells without evidence of toxicity. Finally, we selected populations of AML cells resistant to TAK-243 and identified missense mutations in the adenylation domain of UBA1. Thus, our data demonstrate that TAK-243 targets AML cells and stem cells and support a clinical trial of TAK-243 in this patient population. Moreover, we provide insight into potential mechanisms of acquired resistance to UBA1 inhibitors.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Barghout SH, Patel PS, Wang X, et al. Preclinical evaluation of the selective small-molecule UBA1 inhibitor, TAK-243, in acute myeloid leukemia. Leukemia. 2018. PMID: 29884901. doi:10.1038/s41375-018-0167-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。